Generic Drug Firms Willing To Do Pediatric Studies If Deferred, NAPM Says
Executive Summary
Generic drug companies are willing to conduct pediatric studies for ANDAed products, if such studies were deferred until after approval, the National Association of Pharmaceutical Manufacturers told the agency in an Oct. 26 citizens petition.
You may also be interested in...
GPIA Takes Firm Stance Against Required Pediatric Studies For Generics
Generic drug sponsors bear no responsibility for pediatric studies for multisource drugs, the Generic Pharmaceutical Industry Association told FDA in March 3 comments on implementation of FDAMA pediatric exclusivity provisions and the agency's pediatric rule.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011